Macquarie Group
HBIO icon

Macquarie Group’s Harvard Bioscience HBIO Stock Holding History

Macquarie Group’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-207
Closed -$7K – 1818
2018
Q4 		$7K Buy
207
+203
+5,075% +$8K ﹤0.01% 1998
2018
Q3 		$0 Buy
+4
New +$224 ﹤0.01% 2198
2018
Q2 		– Sell
-11,041
Closed -$552K – 2220
2018
Q1 		$552K Buy
11,041
+8,565
+346% +$384K ﹤0.01% 1357
2017
Q4 		$82K Buy
2,476
+460
+23% +$15.5K ﹤0.01% 1928
2017
Q3 		$76K Buy
+2,016
New +$59.6K ﹤0.01% 1960

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Macquarie Group's HBIO Position: Q1 2019 in Review

Macquarie Group sold out of Harvard Bioscience (HBIO) in Q1 2019, closing a stake of 207 shares — an estimated $7K sold.

Macquarie Group first reported a position in HBIO in Q3 2017 and held it in 5 quarters. The position peaked at $552K in Q1 2018. 87 funds tracked by Wall St. Rank hold HBIO as of Q1 2019.

  • Macquarie Group reported no remaining Harvard Bioscience position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 207 Harvard Bioscience shares in Q1 2019, an estimated $7K.
  • Macquarie Group first reported a position in Harvard Bioscience in Q3 2017 and held it in 5 quarters.
  • Macquarie Group's Harvard Bioscience position peaked at $552K in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.